UC San Diego Study Finds Keto Diet Helps 72% of Anorexia Patients Recover

Why It Matters

Anorexia nervosa remains a lethal and treatment‑resistant disorder, with limited options beyond weight restoration and psychotherapy. Demonstrating that a ketogenic diet can significantly reduce diagnostic scores introduces a metabolic dimension to treatment, potentially expanding the therapeutic toolkit. Moreover, the study highlights the importance of interdisciplinary care—combining nutrition, psychiatry and peer support—to safely implement novel dietary interventions. If subsequent trials confirm these findings, insurers and healthcare systems may need to reconsider coverage policies for diet‑based therapies, and medical curricula could incorporate metabolic neuroscience into eating‑disorder training. Conversely, premature adoption without robust evidence could expose patients to unnecessary risks, making the ongoing debate about safety and oversight critical for policy makers and clinicians alike.

Key Takeaways

• UC San Diego pilot study: 13 of 18 women (72%) fell below anorexia diagnostic thresholds after 14 weeks on a ketogenic diet.
• Participants maintained a healthy‑to‑slightly‑underweight BMI and showed significant reductions in depression scores.
• Guido Frank, UCSD psychiatry professor, attributes recovery to restored brain energy metabolism via ketone bodies.
• UCLA eating‑disorder expert Sahib Khalsa warns against unsupervised keto use and calls for larger randomized trials.
• Researchers plan a multi‑site randomized controlled trial later in 2026 to validate efficacy and safety.

Pulse Analysis

The keto‑anorexia study arrives at a moment when the nutrition field is increasingly intersecting with neuropsychiatry. Historically, the ketogenic diet was relegated to epilepsy treatment; its resurgence for mental health reflects a broader shift toward metabolic therapeutics. This pilot suggests that altering cerebral fuel sources can modulate pathological reward circuits, a hypothesis that aligns with emerging data on glucose‑utilization deficits in mood disorders.

From a market perspective, a validated metabolic therapy could spawn a new niche for specialized diet‑program providers, insurance reimbursement models, and digital health platforms offering supervised keto plans. Companies that already deliver medically‑supervised nutrition programs may see an opportunity to expand into eating‑disorder care, potentially attracting venture capital seeking to address high‑mortality conditions. However, the risk of commercializing a diet that mimics starvation without rigorous oversight could provoke regulatory scrutiny, especially if adverse events arise.

Looking ahead, the key determinant will be the outcomes of the upcoming randomized trial. Should it confirm the pilot’s efficacy, the field may witness a paradigm shift where metabolic re‑education becomes a first‑line adjunct to psychotherapy. If results are mixed or safety concerns dominate, the keto approach may remain a fringe, tightly controlled experimental option. Either way, the study forces clinicians, researchers and policymakers to confront the complex interplay between diet, brain metabolism and mental health, setting the agenda for the next wave of nutrition‑based interventions in psychiatry.